<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02824731</url>
  </required_header>
  <id_info>
    <org_study_id>STR - ProtoChoice-Hirn - 2015</org_study_id>
    <nct_id>NCT02824731</nct_id>
  </id_info>
  <brief_title>Comparison of Proton and Photon Radiotherapy of Brain Tumors (ProtoChoice-Hirn)</brief_title>
  <official_title>Comparison of Proton and Photon Radiotherapy of Brain Tumors: Efficiency and Side Effects in Clinical Standard Doses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Radiation Research in Oncology Dresden/Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol compares the toxicity of radiotherapy or radiochemotherapy applied with&#xD;
      different radiation modalities - protons or photons. Patients with different kinds of brain&#xD;
      tumours and foreseen high-dose radiotherapy can be included. The hypothesis of the trial is&#xD;
      that the rate of chronic toxicity 1 year after the end of radiotherapy is 15% lower after&#xD;
      proton compared to photon treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-randomised 2-arm phase II trial on comparison of proton versus photon radiotherapy in&#xD;
      brain tumours using standard doses and standard combined chemotherapy protocols. Patients are&#xD;
      assigned to the treatment groups by their own choice or availability of the treatment.&#xD;
      Patients are stratified into 4 groups, (1) supratentorial grad III/ IV tumours without&#xD;
      pre-irradiation; (2) supratentorial grade I/II tumours without pre-irradiation; (3)&#xD;
      infratentorial tumours without pre-irradiation; (4) patients with pre-irradiation &gt;40 Gy in&#xD;
      the tumour area. Radiotherapy doses of 54-60 Gy(RBE) are applied in group 1-3 using normal&#xD;
      fractionated schedules. In group 4, 30 Gy(RBE)/ 5 Gy(RBE) per fraction or 36 Gy(RBE) with 2&#xD;
      Gy(RBE) per fraction are allowed. Primary endpoint is chronic toxicity and quality of life.&#xD;
      The hypothesis of the trial is that the rate of chronic toxicity 1 year after the end of&#xD;
      radiotherapy is 15% lower after proton compared to photon treatment. Events for chronic&#xD;
      toxicity are toxicities observed later than 3 months after end of radiotherapy and scored&#xD;
      CTC-AE4.0 &gt;grade 2 or a decrease in Quality of life by &gt;10% (EORTC-QLQ C30 and BN20) or a&#xD;
      decrease in neuropsychological functioning by &gt;10% (MoCa test). All statistical calculations&#xD;
      apply to group (1), i.e. supratentorial grade II/IV tumours without pre-irradiation, all&#xD;
      other arms are closed when group (1) is closed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>late toxicity as cumulative measure</measure>
    <time_frame>1 year after end of treatment</time_frame>
    <description>Events for the endpoint are:&#xD;
any late toxicity CTCAE 4.0 ≥ grade II (except pre-existing conditions)&#xD;
decrease in Quality of life (EORTC-QLQ-C30 and BN20) by &gt;10%&#xD;
decrease in brain function (MOCA test) by more than 10%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local tumour control</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>Local tumour control as Regression or stable disease measured in follow-up MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute toxicity</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>acute toxicity according to CTCAE4.0 score &gt;/= grade II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late toxicity as cumulative measure</measure>
    <time_frame>2 years</time_frame>
    <description>Events for the endpoint are:&#xD;
any late toxicity CTCAE 4.0 ≥ grade II (except pre-existing conditions)&#xD;
decrease in Quality of life (EORTC-QLQ-C30 and BN20) by &gt;10%&#xD;
decrease in brain function (MOCA test) by more than 10%</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">346</enrollment>
  <condition>Brain Tumors</condition>
  <arm_group>
    <arm_group_label>supratentorial, grade III/IV, photon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>supratentorial, grade III/IV, proton</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>supratentorial, grade I/II, photon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients, bening tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>supratentorial, grade I/II, proton</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients, bening tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>infratentorial, photon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>infratentorial, proton</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pre-radiation, photon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&gt; 40Gy in the region of recurrence. Radiation with photons normofractionated 54-60 Gy(RBE) or 5 Gy(RBE)/fraction until 30 Gy(RBE) or normofractionated 36 Gy(RBE).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pre-radiation, proton</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&gt; 40Gy in the region of recurrence. Radiation with protons normofractionated 54-60 Gy(RBE) or 5 Gy(RBE)/fraction until 30 Gy(RBE) or normofractionated 36 Gy(RBE).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation with protons</intervention_name>
    <arm_group_label>infratentorial, proton</arm_group_label>
    <arm_group_label>pre-radiation, proton</arm_group_label>
    <arm_group_label>supratentorial, grade I/II, proton</arm_group_label>
    <arm_group_label>supratentorial, grade III/IV, proton</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation with photons</intervention_name>
    <arm_group_label>infratentorial, photon</arm_group_label>
    <arm_group_label>pre-radiation, photon</arm_group_label>
    <arm_group_label>supratentorial, grade I/II, photon</arm_group_label>
    <arm_group_label>supratentorial, grade III/IV, photon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  primary brain tumor: gliomas (low or high grade), intracerebral meningiomas, pituitary&#xD;
             adenomas, craniopharyngioma and other rare brain tumors&#xD;
&#xD;
          -  brain tumor recurrence without pre-irradiation&#xD;
&#xD;
          -  brain tumor recurrence with pre-irradiation &gt; 40 Gy in the overlap region with the&#xD;
             recurrence region&#xD;
&#xD;
          -  indication for radiotherapy or radiochemotherapy&#xD;
&#xD;
          -  Both proton and photon therapy are possible from a medical point of view (that is no&#xD;
             standard indication for protons or standard indication for example one-time stereotaxy&#xD;
&#xD;
          -  age &gt;= 18 years&#xD;
&#xD;
          -  general condition ECOG ≤ 2, outpatient basis possible&#xD;
&#xD;
          -  indication for high dose (except group 4) radiotherapy or radiochemotherapy&#xD;
&#xD;
          -  capacity to consent and present written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  lack of capacity to consent or lack of written consent&#xD;
&#xD;
          -  cerebral lymphomas&#xD;
&#xD;
          -  brain metastases&#xD;
&#xD;
          -  very small tumors (for example acoustic neuromas, very small recurrences) for this is&#xD;
             a proton therapy from a medical point of view no alternative to a stereotactic&#xD;
             radiotherapy&#xD;
&#xD;
          -  inability to MRI planning (eg. contraindications to performing MRI)&#xD;
&#xD;
          -  lack of compliance of the patient&#xD;
&#xD;
          -  lack of or limited possibility of a reproducible storage (eg by severe restriction of&#xD;
             mobility of the patient)&#xD;
&#xD;
          -  missing or limited possibility of regular follow-up visits in accordance with the&#xD;
             study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mechthild Krause, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Technology, University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology, German Consortium for Translational Cancer Research (DKTK)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mechthild Krause, Prof.</last_name>
    <phone>+49 351 458 5441</phone>
    <email>mechthild.krause@uniklinikum-dresden.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Carl Gustav Carus, Department of Radiotherapy and Radiation Oncology</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mechthild Krause, Prof.</last_name>
      <phone>+49 351 458 5441</phone>
      <email>mechthild.krause@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 11, 2016</study_first_submitted>
  <study_first_submitted_qc>July 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität Dresden</investigator_affiliation>
    <investigator_full_name>Mechthild Krause</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>brain tumors</keyword>
  <keyword>proton radiotherapy</keyword>
  <keyword>photon radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

